<DOC>
	<DOC>NCT02153086</DOC>
	<brief_summary>The purpose of this survey is to examine the safety and efficacy of long-term use of ramelteon tablets (Rozerem 8 mg Tablets) in participants with difficulty falling asleep associated with insomnia in daily medical practice.</brief_summary>
	<brief_title>Ramelteon 8 mg Tablets Specified Drug-use Survey: &lt;Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep&gt; − Transitional Survey From the Preceding Drug-use Survey −</brief_title>
	<detailed_description>This survey was designed to examine the safety and efficacy of long-term use of ramelteon tablets (Rozerem 8 mg Tablets) in participants with difficulty falling asleep associated with insomnia in daily medical practice.The usual dosage for adults is 8 mg of ramelteon administered orally once daily at bedtime.</detailed_description>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Participants with difficulty falling asleep associated with insomnia who have completed a 4week followup in the preceding drug use surveillance and are able to receive continuous administration of Rozerem Tablets Participants with contraindications to Rozerem Tablets. Participants with previous history of hypersensitivity to ingredients in Rozerem Tablets. Participants with severe liver dysfunction. Participants taking fluvoxamine maleate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>